IDRx, Inc.
Cambridge, United States· Est.
An oncology biotech developing rationally designed combination therapies to overcome cancer treatment resistance.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $242M
AI Company Overview
An oncology biotech developing rationally designed combination therapies to overcome cancer treatment resistance.
Oncology
Technology Platform
A platform for the rational design and development of synergistic small molecule combination therapies to overcome cancer resistance.
Funding History
2Total raised:$242M
Series B$120M
PIPE$122M
Opportunities
Potential to redefine treatment paradigms in oncology by creating more durable responses through preemptive combination strategies.
Risk Factors
Faces clinical complexity in testing combinations and the risk of unexpected toxicities or lack of synergistic efficacy.
Competitive Landscape
Competes in the crowded oncology field but with a specialized focus on rationally designed combination therapies to address resistance.